AbCellera Biologics(ABCL)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ABCL AbCellera Biologics

盘后交易 10-02 16:36:23 EDT

13.74

-0.17

-1.22%

盘后13.75

+0.01+0.07%

16:30 EDT

最高14.30	最低13.66	成交量369.04万
今开14.10	昨收13.91	日振幅4.62%
总市值44.52亿	流通市值30.37亿	总股本3.24亿
成交额5,130万	换手率1.67%	流通股本2.21亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ABCL","market":"US","secType":"STK","nameCN":"AbCellera Biologics","latestPrice":13.74,"timestamp":1790971200000,"preClose":13.91,"halted":0,"volume":3690385,"hourTrading":{"tag":"盘后","latestPrice":13.75,"preClose":13.74,"latestTime":"16:30 EDT","volume":29184,"amount":401030.272512,"timestamp":1790973040053,"change":0.01,"changeRate":0.000728,"amplitude":0.010917},"delay":0,"changeRate":-0.012221423436376702,"floatShares":221000000,"shares":324000000,"eps":-0.545545,"marketStatus":"盘后交易","change":-0.17,"latestTime":"10-02 16:36:23 EDT","open":14.095,"high":14.303,"low":13.66,"amount":51299680.22727,"amplitude":0.046226,"askPrice":14,"askSize":2,"bidPrice":13.7,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.545545,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1790985600000},"marketStatusCode":4,"adr":0,"listingDate":1607662800000,"exchange":"NASDAQ","adjPreClose":13.91,"preHourTrading":{"tag":"盘前","latestPrice":14.03,"preClose":13.91,"latestTime":"09:29 EDT","volume":26168,"amount":367619.342408,"timestamp":1790947769063,"change":0.12,"changeRate":0.008627,"amplitude":0.020848},"postHourTrading":{"tag":"盘后","latestPrice":13.75,"preClose":13.74,"latestTime":"16:30 EDT","volume":29184,"amount":401030.272512,"timestamp":1790973040053,"change":0.01,"changeRate":0.000728,"amplitude":0.010917},"volumeRatio":0.559511,"impliedVol":0.8571,"impliedVolPercentile":0.1873},"requestUrl":"/m/hq/s/ABCL","defaultTab":"news","newsList":[{"id":"1183840187","title":"异动解读｜AbCellera Biologics盘中下跌8.02%，报11.405美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1183840187","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183840187?lang=zh_cn&edition=full","pubTime":"2026-08-29 00:29","pubTimestamp":1787934564,"startTime":"0","endTime":"0","summary":"8月29日，AbCellera Biologics盘中下跌8.02%，报11.405美元/股，成交额3280.26万美元。AbCellera Biologics所在的生命科学工具和服务行业中，板块整体承压，个股中，Tempus AI跌8.02%，安捷伦科技跌2.79%，赛默飞世尔跌2.05%，艾昆纬跌0.5%，丹纳赫跌0.23%。AbCellera Biologics是一家临床阶段的生物技术公司，专注于发现和开发一流的抗体药物，用于满足高度未满足的医疗需求。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185660795","title":"AbCellera Biologics 宣布超额认购的2亿美元公开发行定价，涵盖普通股与预融资权证","url":"https://stock-news.laohu8.com/highlight/detail?id=1185660795","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185660795?lang=zh_cn&edition=full","pubTime":"2026-08-13 12:06","pubTimestamp":1786594002,"startTime":"0","endTime":"0","summary":"AbCellera Biologics 正式对外披露，其总额达2亿美元、涉及普通股及预融资权证的公开发行项目已获超额认购，并完成最终定价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABCL","BK4535","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113045545","title":"AbCellera Biologics 公开募股定价：每股9.75美元，发行17,435,897股","url":"https://stock-news.laohu8.com/highlight/detail?id=1113045545","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113045545?lang=zh_cn&edition=full","pubTime":"2026-08-13 12:06","pubTimestamp":1786593967,"startTime":"0","endTime":"0","summary":"AbCellera Biologics Inc. 宣布了其公开发行股票的具体定价。此次发行规模为17,435,897股，每股定价为9.75美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4121","ABCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658950452","title":"潮热治疗药物ABCL635中期试验取得积极结果 AbCellera Biologics(ABCL.US)应声大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2658950452","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658950452?lang=zh_cn&edition=full","pubTime":"2026-08-11 07:37","pubTimestamp":1786405068,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4535","BK4121","ABCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101825904","title":"这家生物技术公司的药物或可治疗潮热，利好消息刺激股价上涨33%","url":"https://stock-news.laohu8.com/highlight/detail?id=1101825904","media":"老虎资讯综合","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101825904?lang=zh_cn&edition=full","pubTime":"2026-08-10 22:42","pubTimestamp":1786372970,"startTime":"0","endTime":"0","summary":"与安慰剂相比，单剂量治疗在第四周时显著降低了潮热发作的频率和严重程度。这家生物技术公司周一报告称，其实验性更年期治疗药物ABCL635在一项临床试验中达到了主要疗效终点。AbCellera称，服药患者还报告睡眠质量改善，整体感觉好转。据道琼斯市场数据，这家生物技术公司的股价周一飙升33%，有望创下有史以来最大单日涨幅。AbCellera的股价在2026年已上涨逾一倍，主要受对二期数据读出预期的推动。","market":"us","thumbnail":"https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"这家生物技术公司的药物或可治疗潮热，利好消息刺激股价上涨33%","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABCL"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1177607298","title":"临床中期试验显示实验性药物有效缓解潮热，AbCellera Biologics盘前股价飙升30.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1177607298","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177607298?lang=zh_cn&edition=full","pubTime":"2026-08-10 19:21","pubTimestamp":1786360905,"startTime":"0","endTime":"0","summary":"AbCellera Biologics盘前交易中股价大幅上涨30.5%，这得益于其一款实验性药物在中期临床试验中成功减少了患者的热潮现象。该试验结果令市场投资者信心大增，推动了公司股价的显著攀升。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ABCL","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128037546","title":"AbCellera Biologics：单次给药即实现血管舒缩症状最佳缓解，二期临床数据亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=1128037546","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128037546?lang=zh_cn&edition=full","pubTime":"2026-08-10 19:06","pubTimestamp":1786359963,"startTime":"0","endTime":"0","summary":"AbCellera Biologics 在二期临床试验中取得突破性成果。数据显示，仅仅单次给药便能显著降低血管舒缩症状的发作程度，其效果堪称同类最优。这一里程碑式的发现，为饱受更年期潮热等困扰的患者带来了新的希望，也标志着公司在抗体药物研发领域迈出了坚实的一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ABCL","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172926895","title":"Abcellera 公布 Abcl635 二期临床试验积极顶线结果：显著降低血管舒缩症状频率与严重程度，并展现良好耐受性","url":"https://stock-news.laohu8.com/highlight/detail?id=1172926895","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172926895?lang=zh_cn&edition=full","pubTime":"2026-08-10 19:01","pubTimestamp":1786359679,"startTime":"0","endTime":"0","summary":"Abcellera 宣布，其针对 Abcl635 的二期临床试验取得了积极的顶线数据。研究结果显示，该药物在降低血管舒缩症状的频率和严重程度方面表现出显著成效。同时，其良好的耐受性特征也一并得到证实。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4121","ABCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138034742","title":"AbCellera Biologics 将于2026年8月10日（周一）公布ABCL635治疗中度至重度更年期血管舒缩症状的2期临床试验顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1138034742","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138034742?lang=zh_cn&edition=full","pubTime":"2026-08-08 04:31","pubTimestamp":1786134675,"startTime":"0","endTime":"0","summary":"AbCellera Biologics（ABCL）宣布，预计将在2026年8月10日（周一）发布其候选药物ABCL635针对中度至重度更年期血管舒缩症状（VMS）的2期临床试验顶线数据。这一消息备受市场关注，标志着公司在女性健康领域的研发进程迈入关键节点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4535","ABCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185330982","title":"AbCellera Biologics获2800万美元预付款及里程碑付款与阶梯式版税","url":"https://stock-news.laohu8.com/highlight/detail?id=1185330982","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185330982?lang=zh_cn&edition=full","pubTime":"2026-07-29 19:06","pubTimestamp":1785323188,"startTime":"0","endTime":"0","summary":"AbCellera Biologics公司宣布，将收到一笔高达2800万美元的预付款。除此之外，还有里程碑付款以及阶梯式特许权使用费加持。这笔交易架构颇为复杂，既有前期现金注入，也有后续潜在收益。预付款即刻到账，为研发管线提供弹药。里程碑款项则与特定项目进展挂钩，分期兑现。至于阶梯式版税，会随着产品销售额的攀升而逐步增加。整体来看，这一支付安排既保障了短期资金流，又锁定了长期回报空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999001176.SGD","IBBQ","IE00B19Z3581.USD","BK4532","LU1778281490.HKD","IE00BJT1NW94.SGD","IE00B894F039.SGD","LU0417517546.SGD","BK4585","LU1035775433.USD","LU1069344957.HKD","LU0058720904.USD","LU0432979614.USD","LU0061475181.USD","IE00BFTCPJ56.SGD","SGXZ57979304.SGD","LU1430594728.SGD","SG9999001176.USD","LU2362541273.HKD","LU1674673428.USD","LU0234570918.USD","LU0256863811.USD","LU0823416689.USD","IE00BZ9MQY76.HKD","BK4533","LU2456880835.USD","SG9999013999.USD","LU1093756325.SGD","BBH","LU2462157665.USD","IE00B19Z3B42.SGD","TBXU","BK4535","VRTX","IE00B19Z9Z06.USD","LU1585245621.USD","BK4588","LU0889565916.HKD","IE0002270589.USD","LU0320765992.SGD","PBE","LU0079474960.USD","IE0002141913.USD","LU2362540622.SGD","GNMX","ABCL","BIB","BK4121","IE00B19Z9P08.USD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","LU0109394709.USD","IBB","LU2362541513.USD","LU2417539215.USD","BK4567","LU1674673691.USD","LU2237438978.USD","LU0289739699.SGD","IE0009355771.USD","LU2236285917.USD","LU1093756168.USD","LU2324357040.USD","IE00B4R5TH58.HKD","IDNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147206442","title":"AbCellera携手福泰制药，共同开发针对自身免疫疾病的多特异性T细胞接合器","url":"https://stock-news.laohu8.com/highlight/detail?id=1147206442","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147206442?lang=zh_cn&edition=full","pubTime":"2026-07-29 19:01","pubTimestamp":1785322903,"startTime":"0","endTime":"0","summary":"AbCellera宣布与福泰制药达成合作，旨在共同探索和发现针对自身免疫性疾病及其他适应症的多特异性T细胞接合器。这一战略合作将结合双方的技术优势，致力于在治疗领域开拓创新路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","BK4588","LU0417517546.SGD","ABCL","BK4139","IE00B2B36J28.USD","IE00B19Z3581.USD","IE00B4R5TH58.HKD","BK4535","SG9999001176.SGD","LU2362541513.USD","LU1093756325.SGD","IE00B19Z9P08.USD","LU0109394709.USD","LU1674673428.USD","BIB","LU0823416689.USD","VRTX","GNMX","IE0002270589.USD","BK4585","IE00BJT1NW94.SGD","IE00B894F039.SGD","TBXU","LU1778281490.HKD","LU2417539215.USD","LU0320765992.SGD","BK4533","IE0009355771.USD","LU1430594728.SGD","LU1585245621.USD","IE00B19Z3B42.SGD","LU0889565916.HKD","LU0432979614.USD","LU2362541273.HKD","IBB","LU0079474960.USD","IE0002141913.USD","LU2456880835.USD","IE00BFTCPJ56.SGD","BBH","SG9999001176.USD","LU0061475181.USD","IE00B19Z9Z06.USD","LU0289739699.SGD","LU2462157665.USD","LU2362540622.SGD","SG9999013999.USD","LU1035775433.USD","BK4121","BK4567","LU0058720904.USD","LU0256863811.USD","BK4532","LU1069344957.HKD","LU1093756168.USD","LU1674673691.USD","LU2237438978.USD","LU2236285917.USD","IBBQ","PBE","IE00BJJMRZ35.SGD","LU0234570918.USD","IDNA","SGXZ57979304.SGD","IE00BZ9MQY76.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118168872","title":"AbCellera Biologics合作案：首付5600万美元，每项目期权费或达7.92亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1118168872","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118168872?lang=zh_cn&edition=full","pubTime":"2026-06-17 19:03","pubTimestamp":1781694200,"startTime":"0","endTime":"0","summary":"AbCellera Biologics公司宣布达成一项新的合作，协议包含高达5600万美元的预付款项。此外，针对每个合作项目，未来可能支付的期权费用总额最高可达7.92亿美元。这一合作框架为AbCellera带来了可观的近期资金与潜在的重大远期收益。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","BK4121","BK4532","LU0109394709.USD","LU0889565916.HKD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","LU0154245673.USD","LU0823416689.USD","BK4533","ABCL","BK4007","IE00BN0W2W23.USD","LU0154245756.USD","BK4535","JAZZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147667464","title":"AbCellera Biologics与爵士制药达成合作 后者获抗体独家开发与商业化选择权","url":"https://stock-news.laohu8.com/highlight/detail?id=1147667464","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147667464?lang=zh_cn&edition=full","pubTime":"2026-06-17 19:03","pubTimestamp":1781694194,"startTime":"0","endTime":"0","summary":"AbCellera Biologics宣布，其合作伙伴爵士制药（Jazz Pharmaceuticals PLC）已获得一项独家选择权，可针对双方合作中发现的特定抗体进行后续开发与商业化。此项安排基于双方既有的研发合作框架，标志着合作项目进入了新的阶段。根据协议条款，爵士制药在行使选择权后，将主导这些抗体疗法的进一步开发、监管审批及全球商业化进程。此次合作旨在加速创新抗体疗法的转化，以应对未满足的医疗需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU0109394709.USD","JAZZ","LU0823416689.USD","LU0320765992.SGD","BK4532","LU0154245673.USD","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","BK4121","ABCL","BK4535","LU0154245756.USD","BK4533","IE00BN0W2V16.EUR","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171679179","title":"爵士制药与AbCellera达成合作，共同研发下一代T细胞衔接多特异性抗体","url":"https://stock-news.laohu8.com/highlight/detail?id=1171679179","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171679179?lang=zh_cn&edition=full","pubTime":"2026-06-17 19:02","pubTimestamp":1781694140,"startTime":"0","endTime":"0","summary":"爵士制药与AbCellera Biologics宣布达成一项合作，旨在共同发现新一代的T细胞衔接多特异性抗体。这一联盟标志着两家公司在创新疗法开发领域迈出了重要一步，旨在通过结合各自在抗体发现与药物开发方面的专长，针对肿瘤学等重大疾病领域开发前沿疗法。此类多特异性抗体设计用于精准引导患者自身的T细胞攻击癌细胞，代表了免疫肿瘤学领域一个极具前景的发展方向。此次合作将充分利用AbCellera在抗体发现方面的先进平台与爵士制药在肿瘤学领域的深厚开发及商业化经验，以期加速新型疗法的诞生。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","LU0109394709.USD","BK4535","LU0154245673.USD","IE00BN0W2W23.USD","ABCL","LU0154245756.USD","BK4532","JAZZ","LU0889565916.HKD","BK4007","BK4533","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","LU0823416689.USD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141450899","title":"异动解读 | AbCellera公布Q1业绩及积极临床数据，股价盘后大涨7.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=1141450899","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141450899?lang=zh_cn&edition=full","pubTime":"2026-05-12 04:45","pubTimestamp":1778532341,"startTime":"0","endTime":"0","summary":"AbCellera Biologics（股票代码：ABCL）今日盘后股价大幅上涨7.62%，引起了市场的广泛关注。消息面上，公司于盘后交易时段前公布了其2026年第一季度的业务成果，显示财务表现稳健，为后续研发提供了支撑。同时，公司披露了其候选药物Abcl635在一期临床试验中取得的积极中期数据，初步结果显示该药物在安全性和耐受性方面表现良好，并显示出预期的生物活性。这一系列积极的业务和研发进展，增强了市场对AbCellera未来增长潜力和管线价值的信心，被认为是推动其股价在盘后显著上涨的主要原因。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ABCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178219492","title":"AbCellera公布2026年第一季度业绩并宣布Abcl635一期临床试验积极中期数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1178219492","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178219492?lang=zh_cn&edition=full","pubTime":"2026-05-12 04:06","pubTimestamp":1778529999,"startTime":"0","endTime":"0","summary":"AbCellera Biologics (ABCL) 近日公布了其2026年第一季度的业务成果，同时披露了其候选药物Abcl635在一期临床试验中取得的积极中期数据。\n公司本季度的财务表现稳健，为后续的研发推进提供了有力支撑。此次公布的临床数据则成为市场关注的另一焦点，初步结果显示Abcl635在安全性和耐受性方面表现良好，并显示出预期的生物活性，为下一阶段的临床开发奠定了坚实基础。\n这一系列进展标志着AbCellera在推进其创新疗法管线方面取得了重要里程碑。公司表示将继续推进Abcl635的临床研究，并致力于利用其领先的抗体发现平台为患者带来新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ABCL","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165209231","title":"财报前瞻｜AbCellera Biologics本季度营收预计降24.00%，机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1165209231","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165209231?lang=zh_cn&edition=full","pubTime":"2026-05-03 08:02","pubTimestamp":1777766534,"startTime":"0","endTime":"0","summary":"AbCellera Biologics将于2026年05月10日盘后披露财报，市场关注收入确认节奏对单季波动与利润率路径的影响。市场一致预期本季度AbCellera Biologics营收约572.11万美元，同比下降24.00%；调整后每股收益为-0.19，同比下降34.98%；目前一致预期中未见对本季度毛利率与净利润的明确数据，公司与机构尚未形成公开口径，本文不展示相关预测。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻｜AbCellera Biologics本季度营收预计降24.00%，机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516608444","title":"Abcellera Biologics Inc.盘中异动 早盘快速下跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516608444","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516608444?lang=zh_cn&edition=full","pubTime":"2025-03-04 23:20","pubTimestamp":1741101638,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日23时20分，Abcellera Biologics Inc.股票出现异动，股价急速下跌5.03%。Abcellera Biologics Inc.股票所在的生物技术行业中，整体涨幅为0.42%。Abcellera Biologics Inc.公司简介：AbCelera Biologics Inc 是一家抗体发现和开发引擎公司，专门设计用于解决传统发现的障碍，以更高的精度和速度找到最佳的临床候选药物，更快地到达诊所和患者面前。借助综合AbCelera平台，公司的专家可以搜索各种不同的抗体，从而快速筛选出有效和可开发的先导药物，帮助合作伙伴取得持久的成功。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304232039963952ca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304232039963952ca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4121","ABCL","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516320356","title":"Abcellera Biologics Inc.盘中异动 股价大跌5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516320356","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516320356?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:57","pubTimestamp":1741013862,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时57分，Abcellera Biologics Inc.股票出现波动，股价急速下跌5.19%。Abcellera Biologics Inc.股票所在的生物技术行业中，整体涨幅为0.02%。Abcellera Biologics Inc.公司简介：AbCelera Biologics Inc 是一家抗体发现和开发引擎公司，专门设计用于解决传统发现的障碍，以更高的精度和速度找到最佳的临床候选药物，更快地到达诊所和患者面前。AbCelera利用专有硬件、软件和工具以及最新的数据科学，作为战略合作伙伴运营，并帮助更快地为任何项目开发优化的解决方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032257429637b36c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032257429637b36c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4535","ABCL","BK4121"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abcellera.com","stockEarnings":[{"period":"1week","weight":0.0996},{"period":"1month","weight":0.2332},{"period":"3month","weight":0.7152},{"period":"6month","weight":2.9517},{"period":"1year","weight":1.3339},{"period":"ytd","weight":3.0673}],"compareEarnings":[{"period":"1week","weight":-0.0042},{"period":"1month","weight":0.0029},{"period":"3month","weight":0.0258},{"period":"6month","weight":0.1649},{"period":"1year","weight":0.1429},{"period":"ytd","weight":0.1204}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"AbCellera Biologics Inc.于2012年11月8日根据不列颠哥伦比亚省商业公司法成立并开始经营活动。该公司是一家临床阶段的生物技术公司，专注于发现和开发一流的抗体药物，用于满足高度未满足的医疗需求。该公司已经建立了一个推进抗体药物项目的平台，他们认为该平台在解决复杂的跨膜蛋白和包括多特异性和抗体药物偶联物在内的新模式等具有挑战性的高价值靶点方面为他们提供了竞争优势。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.002724},{"month":2,"riseRate":0,"avgChangeRate":-0.119779},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.059327},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.055905},{"month":5,"riseRate":0.666667,"avgChangeRate":0.054331},{"month":6,"riseRate":0.5,"avgChangeRate":0.144975},{"month":7,"riseRate":0.5,"avgChangeRate":-0.006532},{"month":8,"riseRate":0.5,"avgChangeRate":0.100971},{"month":9,"riseRate":0.666667,"avgChangeRate":0.075704},{"month":10,"riseRate":0.5,"avgChangeRate":-0.003277},{"month":11,"riseRate":0.6,"avgChangeRate":-0.007841},{"month":12,"riseRate":0.2,"avgChangeRate":-0.030878}],"exchange":"NASDAQ","name":"AbCellera Biologics","nameEN":"AbCellera Biologics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"AbCellera Biologics(ABCL)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供AbCellera Biologics(ABCL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"AbCellera Biologics,ABCL,AbCellera Biologics股票,AbCellera Biologics股票老虎,AbCellera Biologics股票老虎国际,AbCellera Biologics行情,AbCellera Biologics股票行情,AbCellera Biologics股价,AbCellera Biologics股市,AbCellera Biologics股票价格,AbCellera Biologics股票交易,AbCellera Biologics股票购买,AbCellera Biologics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"AbCellera Biologics(ABCL)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供AbCellera Biologics(ABCL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}